Treasury proposal would sharply limit U.S. investment in much of Chinese biotechnology

A proposed Treasury Department regulation would impose broad limits on the types of pharmaceutical and biotechnology assets that U.S. companies and venture capitalists could…

Sign up to read this article for free.

Get free access to a limited number of articles and choose newsletters to go straight to your inbox.